Global Blood Therapeutics is shuttering its GBT440 program to treat idiopathic pulmonary fibrosis (IPF). However, it will continue investigating the drug in sickle cell disease.

Global Blood Therapeutics was investing GBT440 in IPF in three proof-of-concept clinical studies. One was a Phase I trial in healthy volunteers dubbed Basecamp. There were two other Phase IIa studies, one in patients with IPF named GBT440-006 and the other named ZEPHYR.

The drug was well tolerated and no safety concerns were observed. GBT440 was designed to improve oxygen saturation and in all three studies seemed to show it was effective at doing so, but not to an extent that would be clinically beneficial.